Module 5

Asynchronous Module and Content Availability

  • The entire module is available asynchronously.
  • Students are encouraged to review the concept maps and PowerPoints available under module five, especially focusing on:
    • Heart failure concept map
    • Heart failure pharmacology
    • Ischemia concept map
    • Ischemia pharmacology

Review and Engagement

  • Prior to diving into new materials such as dyslipidemia, the instructor emphasizes answering questions related to heart failure and ensuring everyone is on the same page.

Questions from Students

  • A student inquires about the differentiation between systolic and diastolic heart failure, leading to a deeper discussion on heart failure mechanisms.

Understanding Heart Failure

Heart Pump Mechanism

  • The heart operates as a pump with two main functions:
    • Filling (Diastole): The period when the ventricles fill with blood.
    • Ejection (Systole): The period when the heart ejects blood.
Key Terms
  • Stroke Volume: The amount of blood ejected during systole.
  • Cardiac Output: The product of stroke volume and heart rate, indicating how much blood is pumped by the heart in a minute:
    Cardiac Output=Stroke Volume×Heart Rate\text{Cardiac Output} = \text{Stroke Volume} \times \text{Heart Rate}

Heart Failure Characteristics

  • Heart failure arises when the heart does not pump effectively, resulting in:
    • Decreased Stroke Volume: Can be due to ineffective diastole or systole.
    • Compensation Mechanisms: Include sympathetic overdrive and the Renin-Angiotensin System (RAS) compensation, leading to remodeling of the heart (hypertrophy or dilation of ventricles).
    • Cardiac Remodeling: Changes the structure of the heart's walls, which can become thick (hypertrophy) or loose (dilation) or stiff (fibrotic).

Ejection Fraction (EF)

  • Definition of Ejection Fraction: The fraction of blood ejected from the left ventricle during systole compared to the total volume at filled diastole.
    • Normal EF range: 55% to 65%.
  • **Types of Heart Failure: **
    • Heart Failure with Preserved Ejection Fraction (HFpEF): Characterized by filling problems (hypertrophied ventricles cannot fill adequately).
    • Heart Failure with Reduced Ejection Fraction (HFrEF): Characterized by squeezing problems (ventricles do not contract effectively), typically leading to ejection fractions below 40%.

Signs and Symptoms of Heart Failure

Left-Sided Heart Failure Symptoms:
  • Congestion occurs in the lungs:
    • Symptoms include:
    • Pulmonary edema
    • Dyspnea (shortness of breath)
    • Orthopnea (difficulty breathing while lying down)
    • Fatigue due to low oxygen supply.
Right-Sided Heart Failure Symptoms:
  • Congestion occurs in the systemic circulation:
    • Symptoms include:
    • Peripheral edema
    • Jugular venous distension (JVD)
    • Fatigue and exhaustion.

Pharmacological Management of Heart Failure

Diuretics

  • First-line treatment for managing fluid overload.
  • Helps reduce congestion but does not slow down the progression of heart failure.

Angiotensin Receptor Neprilysin Inhibitor (ARNI)

  • Combination of an Angiotensin Receptor Blocker (ARB) and a neprilysin inhibitor.
  • Function: To decrease RAS responses and promote natriuresis (salt and water loss).
  • Mechanism of Action:
    • Allows for better fluid management by acting on natriuretic peptides (ANP and BNP).

Digoxin

  • Purpose: Decreases heart rate, increasing time for diastolic filling while improving contractility.
  • Focus: Careful monitoring for electrical problems and potassium levels due to its action on the heart.

Acute Decompensated Heart Failure

  • Situation where the compensatory mechanisms fail, requiring urgent intervention.
  • Use of alpha and beta agonists as emergent rescue medications.

Ischemia and Angina

Ischemia Definition

  • Ischemia occurs when there is insufficient blood supply and oxygen relative to the demands of the myocardium.

Angina Pectoris

  • Defined as chest pain resulting from myocardial ischemia.
  • Can occur due to:
    • Blocked coronary arteries (coronary artery disease) leading to angina.
Types of Angina
  • Stable Angina: Occurs predictably with exertion and is relieved by rest or nitroglycerin.
  • Unstable Angina: Occurs unpredictably and can happen at rest; may signal impending myocardial infarction (MI).

Linking Dyslipidemia to Heart Conditions

Dyslipidemia Overview

  • The imbalance of lipids within the bloodstream can lead to:
    • Elevated LDL levels
    • Low HDL levels
    • Elevated triglycerides

Lipid Metabolism

  • Ingestion of dietary fats leads to the production of lipoproteins in the liver (VLDL, LDL, HDL).
Key Lipoproteins
  • VLDL (Very Low-Density Lipoprotein): Carry triglycerides.
  • LDL (Low-Density Lipoprotein): Transport cholesterol and can lead to atherosclerosis.
  • HDL (High-Density Lipoprotein): Collects excess cholesterol and returns it to the liver for excretion.

Atherosclerosis Mechanism

  1. Excess LDL leads to inflammation in blood vessels, forming plaques.
  2. Resulting atherosclerosis reduces blood flow to the heart, which can lead to angina and heart failure.

Pharmacologic Treatment of Dyslipidemia

Statins

  • Primary treatment for lowering LDL and raising HDL.
  • Mechanism: Inhibit HMG-CoA reductase (the enzyme responsible for cholesterol synthesis in the liver).

Risks Associated with Statins

  • Myopathy, rhabdomyolysis, liver injury, increased muscle pain, creatinine kinase monitoring.
  • Be cautious with drug interactions (e.g., grapefruit juice).

Ezetimibe

  • Reduces cholesterol absorption in the intestines, further managing dyslipidemia alongside statins.

Bile Acid Sequestrants

  • Help eliminate cholesterol by binding bile outside the intestine.
  • Monitor for GI disturbances and potential drug-drug interactions.

Fibrates

  • Primarily target lowering triglycerides and raising HDL.
  • Can cause GI upset and monitor for myopathy.

PCSK9 Inhibitors

  • Monoclonal antibodies that increase LDL receptor availability in the liver, enhancing LDL clearance from the bloodstream.
  • Monitor for allergic reactions and injection site issues.

Conclusion

  • The seamless connection between coronary artery disease, ischemia, and heart failure through dyslipidemia highlights the importance of comprehensive management of lipid levels to prevent these comorbid conditions.